1Yang JJ,Xiang Y, Wan XR, et al. Prognosis of malignant gestational trophoblastic neoplasia- 20 years of experience[J].J Reprod Med, 2008,53 (8) : 600-607.
2Drake RD,Rao GG,McIntire DD,et al. Gestational trophoblastic disease among Hispanic women, A 21-year hospital-based study [J]. Gynecol Oncol,2006,103(1) :81-86.
3Andrijono A, Muhilal M. Prevention of post-mole malignant trophoblastic disease with vitamin A[J]. Asian Pac J Cancer Prey,2010,11 (2) :567-570.
7Goldstein DP, Berkowitz RS. Current management of gestational trophoblastic neoplasia[J]. Hematol Oncol Clin North Am, 2012,26 (1) :111-131.
二级参考文献8
1Gomperts BN,Belperio JA,Fishbein MC,et al.Keratinocyte growth factor improves repair in the injured tracheal epithelium.Am J Respir Cell Mol Biol,2007,37(1):48.
2Ceccaralli S,Cardinali G,Aspire N,et al.Cortactin involvement in the keratinocyte factor and fibroblast growth factor 10 promotion of migration cortical actin assembly in human keratinocytes.Exp Cell Res,2007,313(9):1758.
3Kaminski A,Hahne JC,Haddoutiel M,et al.Tumor-stroma interactions between metastatic cancer cells and fibroblasts.Int J Mol Med,2006,18(5):941.
4Mas VR,Maluf DG,Archer KJ,et al.Angiogenesis soluble factors as hepatocellular carcinoma noninvasive markers for monitoring hepatitis C virus cirrhotic patients awaiting liver transplantation.Trausplantation,2007,84(10):1262.
5Cho K,Ishiwata T,Uchida N,et al.Enhanced expression of keratinocyte growth factor and its receptor correlates with venous invasion in pancreatic cancer.Am J Pathol,2007,170(6):1964.
6Taniguchi F,Harada T,Iwabe T,et al.Aberrant expression of keratinocyte growth factor receptor in ovarian surface epithelial cell of endometrioma.Fertil Steril,2008,89(2):478.
7Manavi M,Hudelist G,Fink-Retter A,et al.Gene profiling in papcell smears of high-risk human papillomavirus-positive squamous cervical carcinoma.Gynecol Oncol,2007,105(2):418.
8Kudo M,Ishiwata T,Nakazawa N,et al.Keratinocyte growth factor-transfection-stimulated adhesion of colorectal cancer cells to extracellular matrices.Exp Mol Pathol,2007,83(3):443.
1Balki M, Tsen L. Oxytocin protocols for cesarean delivery [J]. lnt Anesthesiol Clin, 2014,52 (2) : 48.
2Leduc D, Biringer A, Lee L, et al. Induction of labour [J]. J Obstet Gynaecol Can, 2013,35(9) :840.
3Simpson KR. Clinicians, guide to the use of oxytocin for labor induction and Augmentation[J]. J Midwifery Wom- ens Health, 2011,56(3) :214.
4Hawkins JS, Wing DA. Current pharmacotherapy options for labor induction[J]. Expert Opin Pharmacother, 2012, 13(14):2 005.
5Zhang J, Branch DW, Ramirez MM, et al. Oxytocin regi- men for labor augmentation, labor progression, and peri- natal outcomes[J]. Obstet Gynecol, 2011, 118 (2 Pt 1) : 249.
6Wei SQ, Luo ZC, Qi HP, et al. High-dose vs low-dose oxytocin for labor augmentation: a systematic review[J]. Am J Obstet Gynecol, 2010,203(4) : 296.
7Montufar-Rueda C, Rodriguez L, Jarquin JD, et al. Se- vere postpartum hemorrhage from uterine atony: a multi- centric study[J]. JPregnancy, 2013 : 525914.
8Gizzo S, Patrelli TS, Gangi SD, et al. Which uterotonic is better to prevent the postpartum hemorrhage? Latest news in terms of clinical efficacy, side effects, and con- traindications: a systematic review[J]. Reprod Sci, 2013, 20(9):1 011.
9Tunalp O, Souza JP, Gilmezoglu M. New WHO recom- mendations on prevention and treatment of postpartum hemorrhage[J], lnt d Gynaecol Obstet, 2013,123(3) : 254.
10Aflaifel N, Weeks AD. Active management of the third stage of labour[J]. BMJ, 2012,345: e4 546.
